JP2020122023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020122023A5 JP2020122023A5 JP2020089453A JP2020089453A JP2020122023A5 JP 2020122023 A5 JP2020122023 A5 JP 2020122023A5 JP 2020089453 A JP2020089453 A JP 2020089453A JP 2020089453 A JP2020089453 A JP 2020089453A JP 2020122023 A5 JP2020122023 A5 JP 2020122023A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- unit
- subscript
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CNc(c(*)c(COC)c(*)c1*)c1O* Chemical compound CNc(c(*)c(COC)c(*)c1*)c1O* 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022007056A JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647373P | 2012-05-15 | 2012-05-15 | |
| US61/647,373 | 2012-05-15 | ||
| US201361770983P | 2013-02-28 | 2013-02-28 | |
| US61/770,983 | 2013-02-28 | ||
| US201361773067P | 2013-03-05 | 2013-03-05 | |
| US61/773,067 | 2013-03-05 | ||
| US13/799,244 | 2013-03-13 | ||
| US13/799,244 US9504756B2 (en) | 2012-05-15 | 2013-03-13 | Self-stabilizing linker conjugates |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097123A Division JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007056A Division JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020122023A JP2020122023A (ja) | 2020-08-13 |
| JP2020122023A5 true JP2020122023A5 (cg-RX-API-DMAC7.html) | 2020-09-24 |
| JP7014856B2 JP7014856B2 (ja) | 2022-02-01 |
Family
ID=49584442
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512756A Active JP6423340B2 (ja) | 2012-05-15 | 2013-05-14 | 自己安定化リンカー結合体 |
| JP2018097123A Active JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
| JP2020089453A Expired - Fee Related JP7014856B2 (ja) | 2012-05-15 | 2020-05-22 | 自己安定化リンカー結合体 |
| JP2022007056A Active JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A Pending JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512756A Active JP6423340B2 (ja) | 2012-05-15 | 2013-05-14 | 自己安定化リンカー結合体 |
| JP2018097123A Active JP6709247B2 (ja) | 2012-05-15 | 2018-05-21 | 自己安定化リンカー結合体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022007056A Active JP7431261B2 (ja) | 2012-05-15 | 2022-01-20 | 自己安定化リンカー結合体 |
| JP2024014096A Pending JP2024032941A (ja) | 2012-05-15 | 2024-02-01 | 自己安定化リンカー結合体 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2850094B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6423340B2 (cg-RX-API-DMAC7.html) |
| KR (5) | KR20230113821A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104822656B (cg-RX-API-DMAC7.html) |
| AU (5) | AU2013263002C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014028222A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3131619A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA037203B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2983109T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1207388A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX384366B (cg-RX-API-DMAC7.html) |
| NZ (3) | NZ741211A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201406252WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013173337A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201407369B (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| TWI603741B (zh) | 2011-06-10 | 2017-11-01 | 梅爾莎納醫療公司 | 蛋白質-聚合物-藥物共軛體 |
| CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| MX384366B (es) * | 2012-05-15 | 2025-03-14 | Seagen Inc | Conjugados enlazadores auto-estabilizantes. |
| KR102572149B1 (ko) | 2013-10-11 | 2023-08-30 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
| DK3054991T3 (da) | 2013-10-11 | 2019-05-06 | Mersana Therapeutics Inc | Protein-polymer-lægemiddelkonjugater |
| KR102356814B1 (ko) * | 2013-10-15 | 2022-01-28 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
| CA2932647C (en) | 2013-12-19 | 2022-06-14 | Seattle Genetics, Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| WO2016008112A1 (en) * | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
| ES2987765T3 (es) * | 2014-09-11 | 2024-11-18 | Seagen Inc | Suministro dirigido de sustancias farmacéuticas que contienen amina terciaria |
| CA2962783A1 (en) * | 2014-10-01 | 2016-04-07 | Medimmune, Llc | Method of conjugating a polypeptide |
| EP3210623B1 (en) | 2014-10-24 | 2022-10-05 | NOF Corporation | Antibody-drug complex having cyclic benzylidene acetal linker |
| CA2969689A1 (en) * | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| JP2018502839A (ja) * | 2014-12-09 | 2018-02-01 | アッヴィ・インコーポレイテッド | Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート |
| CA2970155A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
| EP3270965B1 (en) | 2015-03-18 | 2020-05-06 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
| CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
| CN111533778B (zh) * | 2015-07-28 | 2023-04-25 | 上海皓元生物医药科技有限公司 | 一种抗体偶联药物连接子的工业化生产方法 |
| US10689458B2 (en) | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| WO2017165851A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
| EP3442979A4 (en) | 2016-04-04 | 2019-12-18 | Rutgers, the State University of New Jersey | topoisomerase poisons |
| WO2017196598A1 (en) * | 2016-05-10 | 2017-11-16 | Bristol-Myers Squibb Company | Antibody-drug conjugates of tubulysin analogs with enhanced stability |
| CN109641962A (zh) | 2016-06-08 | 2019-04-16 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
| CN109562168A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| CN116173232A (zh) | 2016-06-08 | 2023-05-30 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| JP2019524651A (ja) | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗ｃｄ９８抗体及び抗体薬物コンジュゲート |
| PH12018502602B1 (en) | 2016-06-08 | 2023-08-16 | Abbvie Inc | Anti-egfr antibody drug conjugates |
| JP2019521114A (ja) | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体薬物コンジュゲート |
| MY199278A (en) | 2016-06-08 | 2023-10-24 | Abbvie Inc | Anti-b7-h3 antibodies and antibody drug conjugates |
| CN109562190A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
| KR20190038579A (ko) * | 2016-08-09 | 2019-04-08 | 시애틀 지네틱스, 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| CN118359705A (zh) | 2016-10-19 | 2024-07-19 | 英温拉公司 | 抗体构建体 |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| KR102312222B1 (ko) | 2016-12-22 | 2021-10-12 | 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 | Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체 |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| CN107652219B (zh) | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
| CN111601803A (zh) | 2017-09-08 | 2020-08-28 | 西雅图基因公司 | 微管溶素及其中间体的制备方法 |
| US11707531B2 (en) * | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| SG11202011984UA (en) | 2018-06-05 | 2020-12-30 | King S College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| US20220040320A1 (en) * | 2018-12-21 | 2022-02-10 | Seagen Inc. | Adcs with thiol multiplex linkers |
| WO2020259258A1 (zh) * | 2019-06-28 | 2020-12-30 | 上海复旦张江生物医药股份有限公司 | 一种抗体偶联药物、其中间体、制备方法及应用 |
| CA3152316A1 (en) | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
| US20230173093A1 (en) * | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
| WO2021226454A1 (en) * | 2020-05-08 | 2021-11-11 | Mpeg La, L.L.C. | Linker compounds |
| EP4223741A1 (en) * | 2020-09-29 | 2023-08-09 | Mabwell (Shanghai) Bioscience Co., Ltd. | Preparation method for bis-substituted bridging antibody-drug conjugate |
| CA3200812A1 (en) | 2020-12-04 | 2022-06-09 | Qingsong GUO | Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| CA3254933A1 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| IL320524A (en) * | 2022-10-28 | 2025-06-01 | Lilly Co Eli | Self-hydrolyzing maleimides for bioconjugation |
| TW202435917A (zh) | 2022-11-17 | 2024-09-16 | 美商西雅圖遺傳學公司 | Ceacam5抗體-藥物接合物及其使用方法 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| IL322569A (en) * | 2023-02-09 | 2025-10-01 | Beone Medicines I Gmbh | Self-stabilizing bonding material bracelets |
| WO2024220889A1 (en) | 2023-04-20 | 2024-10-24 | Seagen Inc. | Sting agonist compounds and conjugates thereof |
| WO2024258743A1 (en) | 2023-06-13 | 2024-12-19 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| TW202500198A (zh) * | 2023-06-29 | 2025-01-01 | 瑞士商百濟神州瑞士有限責任公司 | 生物活性偶聯物、其製備方法及用途 |
| WO2025054181A1 (en) | 2023-09-05 | 2025-03-13 | Seagen Inc. | Targeted degrader molecules and ligand drug conjugates thereof |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| WO2025171055A1 (en) | 2024-02-06 | 2025-08-14 | Kumquat Biosciences Inc. | Heterocyclic conjugates and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| WO1994001485A1 (en) * | 1992-07-01 | 1994-01-20 | Akzo Nobel N.V. | Process for the modification of polyphenylene ether resin compositions |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| DE69626849T2 (de) | 1995-12-22 | 2003-12-24 | Bristol-Myers Squibb Co., Princeton | Verzweigte hydrazongruppen enthaltende kuppler |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| KR101520209B1 (ko) * | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
| NZ566982A (en) | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
| ATE527262T1 (de) | 2006-01-25 | 2011-10-15 | Sanofi Sa | Neue tomaymycin derivate enhaltende zytotoxische mittel |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| ES2523033T3 (es) | 2008-03-18 | 2014-11-20 | Seattle Genetics, Inc. | Conjugados enlazadores del fármaco auriestatina |
| RU2503687C2 (ru) | 2008-04-30 | 2014-01-10 | Иммьюноджен, Инк. | Сшивающие реагенты и их применение |
| BRPI0923283A2 (pt) * | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| EP3360879A1 (en) | 2009-02-05 | 2018-08-15 | ImmunoGen, Inc. | Benzodiazepine derivatives as cytotoxic agents |
| PT3903829T (pt) * | 2009-02-13 | 2023-06-02 | Immunomedics Inc | Imunoconjugados com uma ligação intracelular clivável |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| RS52983B (sr) | 2010-04-15 | 2014-02-28 | Spirogen Sárl | Pirolobenzodiazepini i njihovi konjugati |
| TWI545134B (zh) * | 2010-10-22 | 2016-08-11 | 西雅圖遺傳學公司 | 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效 |
| RS58620B1 (sr) | 2011-02-15 | 2019-05-31 | Immunogen Inc | Metodi pripremanja konjugata |
| MX384366B (es) * | 2012-05-15 | 2025-03-14 | Seagen Inc | Conjugados enlazadores auto-estabilizantes. |
| WO2014151030A1 (en) * | 2013-03-15 | 2014-09-25 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
-
2013
- 2013-05-14 MX MX2019012201A patent/MX384366B/es unknown
- 2013-05-14 CN CN201380025771.XA patent/CN104822656B/zh active Active
- 2013-05-14 KR KR1020237024059A patent/KR20230113821A/ko not_active Ceased
- 2013-05-14 NZ NZ74121113A patent/NZ741211A/en not_active IP Right Cessation
- 2013-05-14 AU AU2013263002A patent/AU2013263002C1/en not_active Ceased
- 2013-05-14 SG SG11201406252WA patent/SG11201406252WA/en unknown
- 2013-05-14 BR BR112014028222A patent/BR112014028222A2/pt not_active Application Discontinuation
- 2013-05-14 JP JP2015512756A patent/JP6423340B2/ja active Active
- 2013-05-14 KR KR1020227042635A patent/KR102557309B1/ko active Active
- 2013-05-14 MX MX2014013807A patent/MX368678B/es active IP Right Grant
- 2013-05-14 CA CA3131619A patent/CA3131619A1/en not_active Abandoned
- 2013-05-14 KR KR1020147034652A patent/KR102144069B1/ko active Active
- 2013-05-14 EA EA201401254A patent/EA037203B1/ru unknown
- 2013-05-14 EP EP13791383.6A patent/EP2850094B1/en active Active
- 2013-05-14 CN CN201810349815.9A patent/CN108465112B/zh active Active
- 2013-05-14 HK HK15108030.8A patent/HK1207388A1/xx unknown
- 2013-05-14 NZ NZ724892A patent/NZ724892A/en not_active IP Right Cessation
- 2013-05-14 WO PCT/US2013/040951 patent/WO2013173337A2/en not_active Ceased
- 2013-05-14 NZ NZ630870A patent/NZ630870A/en not_active IP Right Cessation
- 2013-05-14 ES ES13791383T patent/ES2983109T3/es active Active
- 2013-05-14 SG SG10201608904YA patent/SG10201608904YA/en unknown
- 2013-05-14 KR KR1020207022850A patent/KR102433686B1/ko active Active
- 2013-05-14 KR KR1020217023061A patent/KR102475777B1/ko active Active
- 2013-05-14 CA CA2869777A patent/CA2869777C/en active Active
-
2014
- 2014-10-10 ZA ZA2014/07369A patent/ZA201407369B/en unknown
-
2018
- 2018-02-19 AU AU2018201190A patent/AU2018201190B2/en not_active Ceased
- 2018-05-21 JP JP2018097123A patent/JP6709247B2/ja active Active
-
2020
- 2020-04-28 AU AU2020202805A patent/AU2020202805B2/en not_active Ceased
- 2020-05-22 JP JP2020089453A patent/JP7014856B2/ja not_active Expired - Fee Related
-
2021
- 2021-03-16 AU AU2021201636A patent/AU2021201636B2/en not_active Ceased
-
2022
- 2022-01-20 JP JP2022007056A patent/JP7431261B2/ja active Active
-
2023
- 2023-05-15 AU AU2023203005A patent/AU2023203005A1/en not_active Abandoned
-
2024
- 2024-02-01 JP JP2024014096A patent/JP2024032941A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020122023A5 (cg-RX-API-DMAC7.html) | ||
| JP6709247B2 (ja) | 自己安定化リンカー結合体 | |
| TWI804499B (zh) | Ror1抗體免疫接合物 | |
| AU2023201373A1 (en) | Hydrophilic antibody-drug conjugates | |
| JP7320455B2 (ja) | 親水性リンカーおよびそのコンジュゲート | |
| JP5314590B2 (ja) | カンプトテシン結合部分 | |
| JP2023082171A (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
| CN101969970B (zh) | 用抗体-药物偶联物联合治疗 | |
| CN112543752B (zh) | 连接子、含连接子的抗体偶联药物及连接子的用途 | |
| JP2015524796A5 (ja) | 細胞毒性剤と細胞結合受容体との共役体 | |
| JP7335957B2 (ja) | 抗体－ａｌｋ５阻害剤コンジュゲートおよびその使用 | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP2024075771A (ja) | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 | |
| JP2005521389A5 (cg-RX-API-DMAC7.html) | ||
| JP2013505944A (ja) | Ｄｒ５リガンド薬物結合体 | |
| WO1997046260A1 (fr) | Complexes medicamenteux | |
| JP2009529522A (ja) | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 | |
| JP7057391B2 (ja) | タンパク薬物複合体で使用するためのリンカーに関連する材料および方法 | |
| JP3340127B2 (ja) | 異常増殖性疾患措置のための抗体接合体 | |
| JP2023541969A (ja) | 可溶性タグを有する分子および関連方法 | |
| JPWO2020200880A5 (cg-RX-API-DMAC7.html) | ||
| CN117838878A (zh) | 抗体-sting激动剂缀合物及其在免疫疗法中的用途 | |
| JP2024506300A (ja) | 免疫刺激化合物及びコンジュゲート体 | |
| JP2023159335A5 (cg-RX-API-DMAC7.html) | ||
| CA3121573A1 (en) | Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof |